Bicycle Therapeutics establishes US Operations and appoints Rosamond Deegan, MBA, as President and Chief Business Officer

CAMBRIDGE, MASS and CAMBRIDGE, UK – May 23, 2016 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles®) platform, announced today it has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as President and Chief Business Officer. In this newly created role, Ms. Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.

Read More